Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT on merger of FocusVision and Confirmit
Mandate

Vinge advises EQT on merger of FocusVision and Confirmit

January 08, 2021 Employment and Benefits Banking and Finance EU, Competition and Regulatory M&A

The Nordic-based PE-forms EQT and Verdance intends to merger their respective portfolio companies FocusVision and Confirmit.

FocusVision was acuiered by EQT 201t and provides software and services for market research. Confirmit was acquired by Verdane 2019 and provides solutions for, inter alia, customer experience and market research. The merger is subject to customary regulatory approvals. 

Vinge’s team consisted of partners Christina Kokko (M&A), Marcus Glader (EU & Competition) and Albert Wållgren (Banking & Finance) and associates Stina Bengtsson (M&A), Pauline Lagerstrand, (Banking & Finance), Ebba Svenburg (Employment), Emma Johansson, Sebastian Örndahl, Anna Grigorian, Xandra Ståhlberg and Alice Noguier (EU & Competition).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026